CEL-SCI Corporation

Biotechnology ResearchVirginia, United States11-50 Employees

CEL-SCI Corporation is a biotechnology research company focused on cancer immunotherapy, aiming to bolster the patient's immune response while it remains intact to improve survival. Its lead approach involves Multikine, an investigational leukocyte interleukin injection given prior to standard treatment to prompt the immune system to target locally advanced head and neck cancers. In a Phase 3 study, the company enrolled 928 patients with newly diagnosed, locally advanced primary squamous cell carcinoma of the head and neck, administering Multikine before surgery and radiochemotherapy, and found that in a defined subset (no nodal involvement, low PD-L1 expression) Multikine significantly improved survival, halving the risk of death at five years compared to control. Multikine has FDA Orphan Drug designation for neoadjuvant therapy in head and neck squamous cell carcinoma. The company is based in Tysons, Virginia, near Washington, D.C., and operates as a small to mid-sized biotechnology firm. In 2026, CEL-SCI participated in the BIO International Convention and announced a formal signing with Saudi Amarox to advance U.S.-Saudi cooperation in cancer care, reflecting ongoing international collaboration efforts.

Sign up for free to view info

Email Format Employee directory